AI English summary of an SEC filing — figures as filed
Moderna MRNAModerna entered into a Credit and Guaranty Agreement on November 19, 2025 with Ares Capital Corporation as administrative agent and collateral agent, providing a credit facility of $1,500,000,000.
Key points
AI summaryModerna entered into a Credit and Guaranty Agreement on November 19, 2025 with Ares Capital Corporation as administrative agent and collateral agent, providing a credit facility of $1,500,000,000.
The company said that of $1,500,000,000, $600,000,000 will be funded as an initial term loan and $900,000,000 will be available as delayed draw term loans. The first $400,000,000 of delayed draw term loans will be available from closing until November 2027, and the additional $500,000,000 of delayed draw term loans will be available until November 2028, contingent on the achievement of key regulatory milestones.
The company said the loans will accrue interest at Term SOFR plus an applicable margin of 5.50% per annum or at the base rate plus an applicable margin of 4.50% per annum, and the term loans have a maturity date of November 24, 2030.
Moderna said the loans are guaranteed by its United States, Canadian, United Kingdom, Swiss and Australian subsidiaries and secured by an all asset collateral grant, and are subject to a minimum liquidity covenant requiring minimum cash and cash equivalents of $500,000,000 on the last business day of each week. The company added this requirement increases to $750,000,000 if over $1,000,000,000 is drawn under the Credit Agreement, and the covenant is not required to be tested if the trailing 30 day average market capitalization exceeds $5,000,000,000.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
$1,500,000,000 Credit Facility Entered Into
Moderna entered into a Credit and Guaranty Agreement on November 19, 2025 with Ares Capital Corporation as administrative agent and collateral agent, providing a credit facility of $1,500,000,000.
Source · Based on the filing body and exhibits
Initial Term Loan and Delayed Draw Term Loans Structure
The company said that of $1,500,000,000, $600,000,000 will be funded as an initial term loan and $900,000,000 will be available as delayed draw term loans. The first $400,000,000 of delayed draw term loans will be available from closing until November 2027, and the additional $500,000,000 of delayed draw term loans will be available until November 2028, contingent on the achievement of key regulatory milestones.
Source · Based on the filing body and exhibits
Interest Rate Terms and Maturity November 24, 2030
The company said the loans will accrue interest at Term SOFR plus an applicable margin of 5.50% per annum or at the base rate plus an applicable margin of 4.50% per annum, and the term loans have a maturity date of November 24, 2030.
Source · Based on the filing body and exhibits
Guarantees, Collateral and Minimum Liquidity Requirements
Moderna said the loans are guaranteed by its United States, Canadian, United Kingdom, Swiss and Australian subsidiaries and secured by an all asset collateral grant, and are subject to a minimum liquidity covenant requiring minimum cash and cash equivalents of $500,000,000 on the last business day of each week. The company added this requirement increases to $750,000,000 if over $1,000,000,000 is drawn under the Credit Agreement, and the covenant is not required to be tested if the trailing 30 day average market capitalization exceeds $5,000,000,000.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…